Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes

被引：0
|
作者：
Camelo, Ricardo Mesquita [1 ]
de Medeiros, Tenille Capuxu [2 ]
de Albuquerque, Daniela Goncalves Braz [2 ]
Alvares-Teodoro, Juliana [3 ]
机构：
[1] Univ Fed Minas Gerais, Fac Med, 1020-101 Padre Eustaquio, Belo Horizonte, MG, Brazil
[2] Ctr Hematol & Hemoterapia Rio Grande Norte HEMONOR, Natal, RN, Brazil
[3] Univ Fed Minas Gerais, Fac Farm, Belo Horizonte, MG, Brazil
来源：
HEMATOLOGY TRANSFUSION AND CELL THERAPY | 2023年 / 45卷 / 01期
关键词：
D O I：
10.1016/j.htct.2021.02.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：98 / 101
页数：4
相关论文
共 41 条
  • [31] The efficacy of the rituximab-containing rescue-regimen for severe hemophilia A inhibitor children who relapsed following successful immune tolerance induction with rituximab in China
    Li, Zhengping
    Li, Zekun
    Sun, Jie
    Cheng, Xiaoling
    Liu, Guoqing
    Yao, Wanru
    Huang, Kun
    Ai, Di
    Chen, Zhenping
    Li, Gang
    Zhen, Yingzi
    Poon, Man-Chiu
    Wu, Runhui
    THROMBOSIS RESEARCH, 2023, 223 : 123 - 126
  • [32] Low-Dose Immune Tolerance Induction Therapy for Severe Hemophilia a Inhibitor Patients: Immunosuppressants Improve Outcomes but Are Generally Not Necessary for Inhibitor-Titer below 200 BU/Ml
    Li, Zhengping
    Poon, Man-Chiu
    Wu, Runhui
    BLOOD, 2023, 142
  • [33] Immune Tolerance Induction with High-Dose FVIII and Combined Immunosuppressive Therapy in a Patient with Severe Hemophilia A and High-Titer Inhibitor
    Ranta, S.
    Petrini, P.
    HAEMOPHILIA, 2016, 22 : 95 - 95
  • [34] Successful immune tolerance induction in a 10-year-old, Filipino boy with severe hemophilia and low titer inhibitor: case report
    Joy Paraiso, Noren
    Ong, Jeannie
    HAEMOPHILIA, 2020, 26 : 34 - 34
  • [35] Low-dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL
    Li Zhengping
    Sun Jie
    Li Zekun
    Chen Zhenping
    Liu Guoqing
    Yao Wanru
    Cheng Xiaoling
    Li Gang
    Zhen Yingzi
    Ai Di
    Zhou Yaohan
    Mao Qianqian
    Poon ManChiu
    Wu Runhui
    儿科学研究（英文）, 2024, 08 (02)
  • [36] Low-dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL
    Li, Zhengping
    Sun, Jie
    Li, Zekun
    Chen, Zhenping
    Liu, Guoqing
    Yao, Wanru
    Cheng, Xiaoling
    Li, Gang
    Zhen, Yingzi
    Ai, Di
    Zhou, Yaohan
    Mao, Qianqian
    Poon, Man-Chiu
    Wu, Runhui
    PEDIATRIC INVESTIGATION, 2024, 8 (02) : 91 - 100
  • [37] Low-dose immune tolerance induction in children with severe hemophilia A with high-titer inhibitors: Type of factor 8 mutation and outcomes
    Sun, Jie
    Li, Zekun
    Li, Gang
    Huang, Kun
    Ai, Di
    Liu, Guoqing
    Yao, Wanru
    Xie, Xingjuan
    Gu, Hao
    Zhen, Yingzi
    Chen, Zhenping
    Wu, Runhui
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (07)
  • [38] Did rituximab (ANTI-CD20) influence the outcome of late Immune Tolerance Induction (ITI) in an adult with severe hemophilia A (HA) and highresponder inhibitor?
    Faradji, A.
    Grunebaum, L.
    Desprez, D.
    Goldbarg, V
    Lavigne-Lissalde, G.
    Dory, A.
    Cecile, Gerout A.
    Chilintseva-Natorov, N.
    Eischen, A.
    Feugeas, O.
    Karcher, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 469 - 470
  • [39] Shorter Time Interval from Inhibitor Detection to Starting Low-Dose Immune Tolerance Induction Therapy Is Associated with Better Inhibitor Eradication Outcomes in Severe Hemophilia a Children with High-Titer Inhibitors in China
    Li, Zhengping
    Poon, Man-Chiu
    Liu, Guoqing
    Li, Zekun
    Sun, Jie
    Wu, Runhui
    BLOOD, 2022, 140 : 2757 - 2758
  • [40] ECONOMIC EVALUATION OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) FOR IMMUNE TOLERANCE INDUCTION (ITI) IN PATIENTS WITH HEMOPHILIA A WHO DEVELOP INHIBITORS UNDER THE BRAZILIAN UNIFIED HEALTH SYSTEM (SUS) PERSPECTIVE
    Teich, V
    Li, N.
    Brito, K.
    Krishnan, S.
    Su, J.
    VALUE IN HEALTH, 2018, 21 : S251 - S251
12345